Abstract BACKGROUND Fibrostenotic stricturing disease affects 30-50% of patients with Crohn’s disease (CD), leading to intestinal resection. Currently, there exists a great medical need to identify biomarkers related to fibrostenotic strictures for optimized patient management. Thus, we investigated PRO-C16 as a biomarker for intestinal fibrosis in patients with CD. METHODS Human serum from two independent […]
Serological assessment of PRO-C16 (type XVI collagen formation) reflects intestinal fibrostenotic strictures in patients with crohn’s disease.
August 8, 2025
BMC Gastroenterol